Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;2(4):138-44.
doi: 10.4103/2279-042X.128142.

Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis

Affiliations

Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis

Seyed Ghafur Mousavi et al. J Res Pharm Pract. 2013 Oct.

Abstract

Objective: Antipsychotic medications are the frontline treatment for the most psychotic disorders. The aim of this study is to compare the onset of action of the first and second generation antipsychotics and the rate of their side-effects in the treatment of acute psychosis.

Methods: In a double-blind, controlled clinical trial, 40 acute psychotic patients were randomly allocated in four groups and treated with each of the four antipsychotics: olanzapine, risperidone, haloperidol or thiothixene. The onset of action of each drug was assessed by the Positive and Negative Symptoms Scale. The data were analyzed by Wilcoxon (Gehan) survival and Log Rank analysis, using SPSS version 20.0.

Findings: Initial response was observed in 97.5% (N = 39) of subjects during 2 weeks of intervention. The mean time to the first response was 6.15 ± 2.9 days and this was significantly shorter for risperidone than others. The most common side-effects were sedation and drug induced Parkinsonism.

Conclusion: Risperidone represented shorter onset of action for the treatment of acute psychotic symptoms compared with olanzapine, haloperidol and thiothixene.

Keywords: Acute psychosis; antipsychotic; onset of action; response; side effect.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Study design flow chart
Figure 2
Figure 2
Time to the first response in four treatment groups

Similar articles

Cited by

References

    1. Lewis S, Escalona PR, Keith SJ. Phenomenology of Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th ed. New York: Lippincott Williams and Wilkins; 2009. pp. 1433–51.
    1. Lieberman JA, Fenton WS. Delayed detection of psychosis: Causes, consequences, and effect on public health. Am J Psychiatry. 2000;157:1727–30. - PubMed
    1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull. 1997;23:637–51. - PubMed
    1. Malla A, Norman R, Schmitz N, Manchanda R, Béchard-Evans L, Takhar J, et al. Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychol Med. 2006;36:649–58. - PubMed
    1. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361–70. - PubMed